Knockout Mouse Project at VelociGene®
The VelociGene division of Regeneron Pharmaceuticals, Inc., is proud to participate in the Knockout Mouse Project (KOMP), an initiative of the National Institutes of Health that aims to generate a comprehensive and public resource comprised of mouse embryonic stem cells containing a null mutation in every gene in the mouse genome.
VelociGene Strategy
September 7, 2006
VelociGene technology selected for the NIH Knockout Mouse Project (KOMP)
More News | Publications
VelociGene technology selected for the NIH Knockout Mouse Project (KOMP)
More News | Publications
Regeneron Will Use its VelociGene® Technology to Target Genes, Providing New Models of Human Disease.
Data Access
Data Access
Fastest from concept to Knockout mice without sacrificing precision and complexity.
Learn about our services
Learn about our services
VelociGene allows scientists to rapidly identify the physical and biological effects
of deleting or over-expressing the target gene. View Slideshow
